rabacfosadine

{{Short description|Chemical compound}}

{{Use dmy dates|date=June 2024}}

{{cs1 config |name-list-style=vanc |display-authors=6}}

{{Drugbox

| image = Rabacfosadine structure.svg

| width = 275

| alt =

| tradename = Tanovea

| Drugs.com = {{drugs.com|vet|tanovea-ca1}}

| DailyMedID = Rabacfosadine

| pregnancy_AU =

| routes_of_administration = Intravenous

| ATCvet = yes

| ATC_prefix = L01

| ATC_suffix = BB90

| legal_AU =

| legal_UK =

| legal_US = Rx-only

| legal_US_comment = {{cite web | title=Tanovea- rabacfosadine succinate injection, powder, for solution | website=DailyMed | date=17 January 2023 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5b36e345-fae9-40ea-a069-6fefba92a89f | access-date=1 July 2024}}

| CAS_number = 859209-74-8

| PubChem = 16047979

| ChEMBL = 1823518

| ChemSpiderID = 4486268

| UNII = M39BO43J9W

| DrugBank = DB12762

| KEGG = D10723

| synonyms = GS-9219

| C = 11| H = 35| N = 8| O = 6| P = 1

| SMILES = CCOC( = O)[C@H](C)NP( = O)(COCCN1C = NC2 = C1N = C(N = C2NC3CC3)N)N[C@@H](C)C( = O)OCC

| StdInChI = 1S/C21H35N8O6P/c1-5-34-19(30)13(3)27-36(32,28-14(4)20(31)35-6-2)12-33-10-9-29-11-23-16-17(24-15-7-8-15)25-21(22)26-18(16)29/h11,13-15H,5-10,12H2,1-4H3,(H2,27,28,32)(H3,22,24,25,26)/t13-,14-/m0/s1

| StdInChIKey = ANSPEDQTHURSFQ-KBPBESRZSA-N

}}

Rabacfosadine, sold under the brand name Tanovea, is a guanine nucleotide analog used for the treatment of lymphoma in dogs. It was developed by Gilead Sciences as GS-9219.{{cite journal | vauthors = De Clercq E | title = Tanovea for the treatment of lymphoma in dogs | journal = Biochemical Pharmacology | volume = 154 | pages = 265–269 | date = August 2018 | pmid = 29778492 | doi = 10.1016/j.bcp.2018.05.010 | doi-access = free }}

The active form of rabacfosadine is a chain-terminating inhibitor of the major deoxyribonucleic acid (DNA) polymerases. In vitro studies have demonstrated that rabacfosadine inhibits DNA synthesis, resulting in S phase arrest and induction of apoptosis.{{cite journal | vauthors = Reiser H, Wang J, Chong L, Watkins WJ, Ray AS, Shibata R, Birkus G, Cihlar T, Wu S, Li B, Liu X, Henne IN, Wolfgang GH, Desai M, Rhodes GR, Fridland A, Lee WA, Plunkett W, Vail D, Thamm DH, Jeraj R, Tumas DB | title = GS-9219--a novel acyclic nucleotide analogue with potent antineoplastic activity in dogs with spontaneous non-Hodgkin's lymphoma | journal = Clinical Cancer Research | volume = 14 | issue = 9 | pages = 2824–32 | date = May 2008 | pmid = 18451250 | doi = 10.1158/1078-0432.CCR-07-2061 | doi-access = free }} It also inhibits the proliferation of lymphocytes in dogs with naturally occurring lymphoma.{{cite journal | vauthors = Lawrence J, Vanderhoek M, Barbee D, Jeraj R, Tumas DB, Vail DM | title = Use of 3'-deoxy-3'-[18F]fluorothymidine PET/CT for evaluating response to cytotoxic chemotherapy in dogs with non-Hodgkin's lymphoma | journal = Veterinary Radiology & Ultrasound | volume = 50 | issue = 6 | pages = 660–8 | date = 2009 | pmid = 19999354 | doi = 10.1111/j.1740-8261.2009.01612.x }}

Rabacfosadine was granted conditional approval by the US Food and Drug Administration (FDA) in December 2016,{{Cite press release |url=https://www.fda.gov/animalveterinary/newsevents/cvmupdates/ucm535190.htm|title=FDA Conditionally Approves Tanovea-CA1, the first New Animal Drug for Treating Lymphoma in Dogs|date=3 January 2017|work=U.S. Food and Drug Administration (FDA) | archive-url=https://web.archive.org/web/20170701171458/https://www.fda.gov/animalveterinary/newsevents/cvmupdates/ucm535190.htm | archive-date=1 July 2017 | url-status=dead }} and became the first medication to receive full approval for the treatment of canine lymphoma in July 2021.